Irbesartan for the treatment of hypertension in patients with the metabolic syndrome:: A sub analysis of the Treat to Target post authorization survey.: Prospective observational, two armed study in 14,200 patients

被引:75
作者
Kintscher, Ulrich [1 ]
Bramlage, Peter [2 ]
Paar, W. Dieter [3 ]
Thoenes, Martin [4 ]
Unger, Thomas [1 ]
机构
[1] Cardiovasc Res Ctr, Inst Pharmacol, Charite, Berlin, Germany
[2] Tech Univ Dresden, Med Fac Carl Gustav Carus, Inst Clin Pharmacol, Dresden, Germany
[3] Sanofi Aventis Deutschland GmbH, Med Affairs CardioVasc Thrombosis, Berlin, Germany
[4] Med Affairs, Sanofi Aventis, Paris, France
关键词
D O I
10.1186/1475-2840-6-12
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: The metabolic syndrome is a cluster of cardiovascular risk factors leading to an increased risk for the subsequent development of diabetes and cardiovascular morbidity and mortality. Blocking the renin-angiotensin system has been shown to prevent cardiovascular disease and delay the onset of diabetes. Irbesartan is an angiotensin receptor blocker (ARB) which has been shown to possess peroxisome proliferator-activated receptor gamma (PPAR.) activating properties, and to have a favorable metabolic profile. Current discussion is whether the addition of small doses of hydrochlorothiazide changes this profile. Therefore the efficacy, safety and metabolic profile of Irbesartan either as monotherapy or in combination therapy was assessed in patients with the metabolic syndrome in a large observational cohort in primary care. Research design and methods: Multicenter, prospective, two-armed, post authorization study over 9 months in 14,200 patients with uncontrolled hypertension with and without the metabolic syndrome (doctors' diagnosis based on the Adult Treatment Panel III criteria 2001). Blood pressure was measured sphygmomanometrically and cardiovascular risk factors making up the criteria for the metabolic syndrome were assessed. Main outcome measures: Systolic (SBP) and diastolic (DBP) blood pressure reduction, - response, and normalization (systolic and diastolic), changes in fasting glucose, waist circumference (abdominal obesity), serum triglycerides and HDL cholesterol as well as the proportion of patients fulfilling the criteria for the metabolic syndrome. Number and nature of adverse events (AEs). Results: After 9 month the use of Irbesartan in monotherapy resulted in a significant reduction of blood pressure (SBP: 26.3 +/- 10.1 mmHg/DBP-13.0 +/- 6.6 mmHg, both p < 0.0001) in patients with the metabolic syndrome. This was accompanied by a reduction in cardiovascular risk factors: HDL cholesterol (+3.6 +/- 7.2 mg/dl in men, +3.8 +/- 6.5 mg/dl in women, both p < 0.0001), serum triglycerides (-28.6 +/- 52.1 mg/dl, p < 0.0001), fasting blood glucose (-8.4 +/- 25.1 mg/ dl, p < 0.0001) and waist circumference (-2.4 +/- 11.9 cm in men, -1.2 +/- 14.2 in women, both p < 0.0001) were significantly improved. Irbesartan combination therapy (12.5 mg HCTZ) in patients with the metabolic syndrome: blood pressure reduction (SBP: -27.5 +/- 10.1 mmHg/DBP: -14.1 +/- 6.6 mmHg, both p < 0.0001), improvement in HDL cholesterol (+4.0 +/- 6.8 mg/dl in men, +3.4 +/- 6.8 in women, both p < 0.0001), triglycerides (-34.1 +/- 52.6 mg/dl, p < 0.0001), fasting blood glucose (-10.0 +/- 24.7, p < 0.0001) and waist circumference (-3.2 +/- 12.7 cm in men, -1.7 +/- 14.4 in women, both p < 0.0001). Tolerability was excellent: only 0.6% of patients experienced an AE. Conclusion: There was a significant improvement in blood pressure and metabolic risk factors as a result of Irbesartan treatment. There was no evidence of a difference between monotherapy and combination therapy with regard to the cardiovascular risk profile.
引用
收藏
页数:11
相关论文
共 38 条
[1]   PPARγ, the ultimate thrifty gene [J].
Auwerx, J .
DIABETOLOGIA, 1999, 42 (09) :1033-1049
[2]   The incidence and persistence of the NCEP (National Cholesterol Education Program) metabolic syndrome.: The French DESIR study [J].
Balkau, B ;
Vernay, M ;
Mhamdi, L ;
Novak, M ;
Arondel, D ;
Vol, S ;
Tichet, J ;
Eschwège, E .
DIABETES & METABOLISM, 2003, 29 (05) :526-532
[3]   Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity [J].
Benson, SC ;
Pershadsingh, HA ;
Ho, CI ;
Chittiboyina, A ;
Desai, P ;
Pravenec, M ;
Qi, NN ;
Wang, JM ;
Avery, MA ;
Kurtz, TW .
HYPERTENSION, 2004, 43 (05) :993-1002
[4]   The effect of irbesartan in reducing cardiovascular risk in hypertensive type 2 diabetic patients: an observational study in 16,600 patients in primary care [J].
Bramlage, P ;
Pittrow, D ;
Kirch, W .
CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 (10) :1625-1631
[5]  
Chalmers J, 1999, J HYPERTENS, V17, P151
[6]   PPAR γ-activating angiotensin type-1 receptor blockers induce adiponectin [J].
Clasen, R ;
Schupp, M ;
Foryst-Ludwig, A ;
Sprang, C ;
Clemenz, M ;
Krikov, M ;
Thöne-Reineke, C ;
Unger, T ;
Kintscher, U .
HYPERTENSION, 2005, 46 (01) :137-143
[7]   Randomized, controlled trials, observational studies, and the hierarchy of research designs. [J].
Concato, J ;
Shah, N ;
Horwitz, RI .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (25) :1887-1892
[8]   Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol [J].
Dahlöf, B ;
Devereux, RB ;
Kjeldsen, SE ;
Julius, S ;
Beevers, G ;
de Faire, U ;
Fyhrquist, F ;
Ibsen, H ;
Kristiansson, K ;
Lederballe-Pedersen, O ;
Lindholm, LH ;
Nieminen, MS ;
Omvik, P ;
Oparil, S ;
Wedel, H .
LANCET, 2002, 359 (9311) :995-1003
[9]   Reasons for not intensifying anti hypertensive treatment (RIAT): a primary care anti hypertensive intervention study [J].
Ferrari, P ;
Hess, L ;
Pechere-Bertschi, A ;
Muggli, F ;
Burnier, M .
JOURNAL OF HYPERTENSION, 2004, 22 (06) :1221-1229
[10]   Hydrochlorothiazide abolishes the anti-atherosclerotic effect of quinapril [J].
Fonseca, FAH ;
Ihara, SSM ;
Izar, MCO ;
Silva, EP ;
Kasinski, N ;
Lopes, IEL ;
Pinto, LESA ;
Paiva, TB ;
Tufik, S ;
de Paola, AAV ;
Carvalho, ACC .
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2003, 30 (10) :779-785